Neuropathic pain: Mechanisms, therapies, and advances.

Marco T. Rossi*

Department of Pain Science, University of Bologna, Italy

Introduction

This review delves into the complex mechanisms driving neuropathic pain, moving from clinical observations to fundamental research. It covers peripheral and central sensitization, focusing on the molecular and cellular changes that contribute to chronic pain states. Understanding these pathways is crucial for developing targeted treatments that address the underlying pathophysiology rather than just symptoms. The discussion highlights the interplay of neuronal hyperexcitability, glial activation, and immune responses in establishing and maintaining neuropathic pain[1].

This narrative review explores spinal cord stimulation (SCS) as an invasive therapy for chronic neuropathic pain. It discusses the evolution of SCS technology, including different waveforms and targeting strategies, and assesses its efficacy and safety profile. The article emphasizes patient selection criteria and the importance of multidisciplinary care in optimizing outcomes for patients undergoing SCS implantation. It suggests that SCS remains a valuable option for refractory neuropathic pain when conservative treatments fail[2].

This overview examines various rehabilitation strategies employed in managing neuropathic pain. It highlights the role of physical therapy, occupational therapy, and psychological interventions, emphasizing a holistic approach. The article discusses how exercise, manual therapy, and patient education can improve function, reduce pain intensity, and enhance quality of life. It also touches on neuromodulation techniques and their integration into comprehensive rehabilitation programs[3].

This systematic review investigates the mechanisms and management of central sensitization in chronic pain. It clarifies how prolonged noxious input leads to heightened pain sensitivity and expanded receptive fields in the central nervous system. The review also explores various therapeutic approaches aimed at targeting central sensitization, including pharmacological, physical, and psychological interventions. It underscores the importance of recognizing and addressing central sensitization for effective chronic pain management[4].

This article provides an evidence-based overview of intrathecal drug delivery (IDD) for chronic pain management. It discusses the indications, patient selection, and clinical outcomes associated with IDD, particularly for refractory neuropathic pain and spasticity. The authors offer recommendations for safe and effective practice, considering various pharmacological agents used in IDD systems. This therapy offers a targeted approach, potentially reducing systemic side effects compared to oral medications[5].

This paper explores recent advancements and future directions in identifying biomarkers for neuropathic pain. It discusses the potential of molecular, neuroimaging, and electrophysiological markers to improve diagnosis, predict treatment response, and stratify patients. The challenges in translating preclinical findings to clinical practice are highlighted, emphasizing the need for robust and validated biomarkers to personalize neuropathic pain management and accelerate drug development[6].

This review summarizes the critical role of neuroinflammation in the pathophysiology of chronic pain. It describes how immune cells and inflammatory mediators in both the peripheral and central nervous systems contribute to the initiation and maintenance of pain hypersensitivity. The article identifies various signaling pathways and cellular interactions involved in neuroinflammation-induced pain, highlighting potential therapeutic targets. Modulating neuroinflammatory processes could offer new avenues for pain relief[7].

This systematic review and meta-analysis assesses the effectiveness of multimodal rehabilitation for chronic neuropathic pain. It synthesizes evidence from various studies, evaluating the impact of integrated physical, psychological, and educational interventions on pain intensity, functional ability, and quality of life. The findings suggest that a comprehensive, multidisciplinary approach is more beneficial than single-modality treatments for patients with persistent neuropathic pain, providing a rationale for its widespread implementation[8].

This narrative review investigates the application of pulsed radiofrequency (PRF) in the treatment of neuropathic pain. It describes the mechanisms of action, clinical indications, and outcomes of PRF for various neuropathic conditions. The article discusses how PRF selectively modulates nerve activity without causing destructive le-

***Correspondence to:** Marco T. Rossi, Department of Pain Science, University of Bologna, Italy. E-mail: marco.rossi@painresearch.unibo.it

Received: 01-May-2025, Manuscript No. AAPMT-25-262; **Editor assigned:** 05-May-2025, Pre QC No. AAPMT-25-262 *(PQ)*; **Reviewed:** 23-May-2025, QC No. AAPMT-25-262; **Revised:** 03-Jun-2025, Manuscript No. AAPMT-25-262 *(R)*; **Published:** 12-Jun-2025, DOI: 10.35841/aapmt-9.3.262

Citation: Rossi MT. Neuropathic pain: Mechanisms, therapies, and advances. J Pain Manage Ther. 2025;09(03):262.

sions, offering a less invasive alternative for pain relief. It highlights areas where PRF shows promise and outlines limitations and future research directions[9].

This article provides an update on recent pharmacological advancements in the treatment of neuropathic pain. It reviews novel drug targets and emerging compounds, alongside optimizing the use of existing medications. The discussion covers advancements in understanding the specific pain mechanisms that these new treatments aim to address, such as sodium channel blockers, GABA modulators, and agents targeting neuroinflammation. It emphasizes the need for individualized pharmacological strategies to improve patient outcomes[10].

Conclusion

Neuropathic pain involves complex mechanisms, including peripheral and central sensitization, neuronal hyperexcitability, glial activation, and neuroinflammation [1, 4, 7]. Understanding these molecular and cellular changes is crucial for developing targeted treatments. Current therapeutic strategies encompass a range of interventions. Invasive options like spinal cord stimulation (SCS), intrathecal drug delivery (IDD), and pulsed radiofrequency (PRF) offer relief, particularly for refractory cases, by modulating nerve activity or delivering targeted medication [2, 5, 9]. SCS technology has evolved, emphasizing patient selection and multidisciplinary care. IDD provides an evidence-based approach for chronic pain and spasticity, while PRF selectively modulates nerves without destructive lesions.

Comprehensive rehabilitation, including physical, occupational, and psychological therapies, is vital for managing neuropathic pain. A multimodal, multidisciplinary approach has shown greater benefits than single-modality treatments, improving function, reducing pain, and enhancing quality of life [3, 8]. The field is also advancing through biomarker discovery, exploring molecular, neuroimaging, and electrophysiological markers for better diagnosis, treatment prediction, and patient stratification [6]. Simultaneously, pharmacological advancements are ongoing, with novel drug targets and compounds addressing specific pain mechanisms like sodium channel blockers, GABA modulators, and neuroinflammation. The ultimate goal across all these approaches is to personalize management and improve patient outcomes [10].

References

1. Nanna BF, Rohini K, Troels SJ. Mechanisms of neuropathic pain: from the clinic to the bench. *Nat Rev Neurosci.* 2021;22(4):237-253.
2. Adnan AK, Jean-Pierre VB, Inge S. Spinal cord stimulation for chronic neuropathic pain: a narrative review. *Pain.* 2019;160(7):1451-1463.
3. Maria V, Beniamino P, Tiziana I. Rehabilitation in Neuropathic Pain: *An Overview. J Clin Med.* 2020;9(1):285.
4. Jo N, Jessica VO, Liesbet DV. Central sensitization and chronic pain: a systematic review of its mechanisms and management. *Pain Med.* 2019;20(10):1990-2002.
5. Timothy RD, Matthew JS, Andrea LR. Intrathecal drug delivery for chronic pain: evidence and recommendations. *Pain Physician.* 2019;22(5):E455-E468.
6. Ralf B, Serge P, Luana C. Biomarkers for neuropathic pain: recent developments and future directions. *Pain.* 2021;162(3):682-687.
7. Miriam RS, Jianzhong M, Jingwu Z. Neuroinflammation and chronic pain: a review of the underlying mechanisms and potential therapeutic targets. *CNS Neurosci Ther.* 2022;28(7):1066-1077.
8. Eloïse L, Samuel H, Isabelle R. Multimodal rehabilitation for chronic neuropathic pain: a systematic review and meta-analysis. *Pain.* 2023;164(7):1456-1466.
9. Eun YC, Jin HK, Dae GL. Pulsed radiofrequency for neuropathic pain: a narrative review. *Korean J Anesthesiol.* 2021;74(2):107-117.
10. Nanna BF, Henriette N, *Morten J. Recent advances in the pharmacological treatment of neuropathic pain. Curr Opin Pharmacol.* 2020;50:1-8.

Citation: *Rossi MT. Neuropathic pain: Mechanisms, therapies, and advances. J Pain Manage Ther. 2025;09(03):262.*